Compare Automatic Data Processing Inc (ADP) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs Neurocrine Biosciences Inc — how do they compare? Automatic Data Processing Inc trades at $270 (market cap $108.72B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Automatic Data Processing Inc is far larger — about 6.5× Neurocrine Biosciences Inc's market cap, and Automatic Data Processing Inc pays a 2.48% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| ADP | NBIX | |
|---|---|---|
Market Cap | $108.72B | $16.76B |
Sector | Industrials | Health |
52-Week High | $309.03 | $185.50 |
52-Week Low | $188.79 | $123.10 |
Enterprise Value | $109.76B | $16.78B |
Dividend Yield | 2.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $271.32, down 0.8% for the day, with strong technical momentum showing bullish moving averages and key support at $269. The company demonstrates robust fundamentals with consistent earnings beats, 20.11% net margins, and 72.24% ROE. Recent Q4 2026 results showed 7% revenue growth and 17% EPS growth, driving positive analyst sentiment despite elevated valuation multiples.
Outlook remains positive with a $280.50 consensus price target offering 3.4% upside potential. Key opportunities include margin expansion and dividend stability, while risks center on high valuation sensitivity and labor market volatility affecting ADP's payroll processing business. The stock presents a quality growth opportunity with disciplined risk management required.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
